Complete Regression of Choroidal Metastasis Secondary to Non-Small-Cell Lung Cancer with Intravitreal Bevacizumab and Oral Erlotinib Combination Therapy
- Authors
- Kim, Seong-Woo; Kim, Myung Jin; Huh, Kuhl; Oh, Jaeryung
- Issue Date
- 2009
- Publisher
- KARGER
- Keywords
- Choroidal metastasis; Non-small-cell lung cancer; Bevacizumab; Erlotinib
- Citation
- OPHTHALMOLOGICA, v.223, no.6, pp.411 - 413
- Indexed
- SCIE
SCOPUS
- Journal Title
- OPHTHALMOLOGICA
- Volume
- 223
- Number
- 6
- Start Page
- 411
- End Page
- 413
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/122178
- DOI
- 10.1159/000229307
- ISSN
- 0030-3755
- Abstract
- Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography ( FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC. Copyright (c) 2009 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.